UAE Influenza Medications Market Report 2022 to 2030

UAE Influenza Medications Market Analysis

$ 3999

UAE influenza medications market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Due to factors such an increase in influenza cases and increasing research and development for drug development initiatives, the global market for anti-flu medications is anticipated to rise. As a result of technological developments that generate a significant pipeline of novel pharmaceuticals, this industry may experience growth. Sanofi S.A, Lupin Limited, Teva Pharmaceutical Industries Ltd, Shionogi & Co. Ltd, Macleods Pharmaceutical Ltd, Alvogen Pvt. Ltd, AstraZaneca Plc, BioCryst Pharmaceuticals Inc, F. Hoffman La Roche Ltd, Novartis AG, Vitaris AG. Are the top key players operating in this market.

ID: IN10AEPH311 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Riddhi Solanki

Buy Now

UAE Influenza Medications Market Analysis Summary

UAE Influenza Medications Market is valued at around $5.4 Mn in 2022 and is projected to reach $8.5 Mn by 2030, exhibiting a CAGR of 5.71% during the forecast period 2023-2030.

Any of numerous closely related viruses in the family Orthomyxoviridae can cause influenza (a group of RNA viruses). There are four different varieties of influenza viruses: A, B, C, and D. Although these primary varieties typically exhibit similar symptoms, their antigens are completely independent, therefore infection with one type does not provide immunity against the others. The large influenza epidemics are brought on by A viruses, while localised outbreaks are more frequently caused by B viruses. Only mild respiratory illnesses in humans are brought on by the C viruses. Only pigs and cattle have been known to contract influenza D viruses, which are not known to infect humans. Two antiviral drugs, amantadine and rimantadine, are efficient therapies for influenza infections brought on by type A viruses. Viral resistance to these drugs, however, is limiting their utility. The more contemporary class of drugs known as neuraminidase inhibitors, which also includes oseltamivir (Tamiflu) and zanamivir (Relenza), inhibits both influenza A and B viruses. Due to factors such an increase in influenza cases and increasing research and development for drug development initiatives, the global market for anti-flu medications is anticipated to rise. As a result of technological developments that generate a significant pipeline of novel pharmaceuticals, this industry may experience growth. Sanofi S.A, Lupin Limited, Teva Pharmaceutical Industries Ltd, Shionogi & Co. Ltd, Macleods Pharmaceutical Ltd, Alvogen Pvt. Ltd, AstraZaneca Plc, BioCryst Pharmaceuticals Inc, F. Hoffman La Roche Ltd, Novartis AG, Vitaris AG. are top key players operating in this market.

Market Dynamics

Market Growth Drivers

Two key drivers driving the growth of the market for influenza treatments are the increased understanding of how influenza impacts human health and the corresponding rise in R&D activity for the release of novel drugs. The majority of influenza treatments currently follow guidelines provided by regulatory bodies like the Centers for Disease Control and Prevention (CDC). The severity and potentially lethal nature of influenza has prompted numerous governmental and non-governmental initiatives to create influenza awareness campaigns. These initiatives have created demand for more treatment options and raised awareness of the issue. The rising incidence of the two influenza kinds and the rising desire for more powerful treatments are additional important variables influencing market developments. Since they were first made available to the public, influenza treatments have experienced significant R&D advancements. However, the U.S. Food and Drug Administration has only approved four key medications for the treatment of influenza, despite the great potential for market expansion due to unmet patient needs (FDA). There are only a few significant participants in this sector, and the effect of the comparably less expensive generics is growing. However, some strains of the illness are very resistant to treatment due to the influenza virus's cyclical nature, and the disease's increasing incidence is further deteriorating the prospects for successful patient treatment. This has created a significant unmet treatment need in the market and is expected to be another important driver driving market demand.

Market Restraints

Although there are antiviral medications and influenza vaccines, they could not provide complete protection from all virus types. The compatibility of the vaccination strains with the circulating strains, an individual's immune response, age, or overall health can all affect how successful a vaccine is. In a manner similar to this, antiviral medications may vary in how efficiently they combat different strains or may function better when given early in the course of an illness, and this will act as challenge in influenza medications market.

Competitive Landscape

Key Players

Sanofi S.A
Lupin Limited
Teva Pharmaceutical Industries Ltd.
Shionogi & Co. Ltd.
Macleods Pharmaceutical Ltd
Alvogen Pvt. Ltd
AstraZaneca Plc.
BioCryst Pharmaceuticals Inc
F. Hoffman La Roche Ltd
Novartis AG
Vitaris AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Influenza Medications Market Segmentation

By Medication

Antiviral Drugs
Antihistamines
Analgesics
Others

By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Route of Administration

Oral
Parenteral
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.